For patients with advanced NSCLC at the time of presentation, it should be evaluated whether there are somatic driver gene mutations, such as EGFR, ALK, ROS1, and BRAFV600E mutations, and whether express programmed cell death ligand 1 (PD-L1). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.